Coverage of primary and booster vaccination against COVID-19 by socioeconomic level: A nationwide cross-sectional registry study
High and equitable COVID-19 vaccination coverage is important for pandemic control and prevention of health inequity. However, little is known about socioeconomic correlates of booster vaccination coverage. In this cross-sectional study of all Norwegian adults in the national vaccination program (N ...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_b97c827da03e482b927ebe61bdbde1cf | ||
042 | |a dc | ||
100 | 1 | 0 | |a Bo T. Hansen |e author |
700 | 1 | 0 | |a Angela S. Labberton |e author |
700 | 1 | 0 | |a Prabhjot Kour |e author |
700 | 1 | 0 | |a Kristian B. Kraft |e author |
245 | 0 | 0 | |a Coverage of primary and booster vaccination against COVID-19 by socioeconomic level: A nationwide cross-sectional registry study |
260 | |b Taylor & Francis Group, |c 2023-01-01T00:00:00Z. | ||
500 | |a 2164-5515 | ||
500 | |a 2164-554X | ||
500 | |a 10.1080/21645515.2023.2188857 | ||
520 | |a High and equitable COVID-19 vaccination coverage is important for pandemic control and prevention of health inequity. However, little is known about socioeconomic correlates of booster vaccination coverage. In this cross-sectional study of all Norwegian adults in the national vaccination program (N = 4,190,655), we use individual-level registry data to examine coverage by levels of household income and education of primary (≥2 doses) and booster (≥3 doses) vaccination against COVID-19. We stratify the analyses by age groups with different booster recommendations and report relative risk ratios (RR) for vaccination by 25 August 2022. In the 18-44 y group, individuals with highest vs. lowest education had 94% vs. 79% primary coverage (adjusted RR (adjRR) 1.15, 95%CI 1.14-1.15) and 67% vs. 38% booster coverage (adjRR 1.55, 95% CI 1.55-1.56), while individuals with highest vs. lowest income had 94% vs. 81% primary coverage (adjRR 1.10, 95%CI 1.10-1.10) and 60% vs. 43% booster coverage (adjRR 1.23, 95%CI 1.22-1.24). In the ≥45 y group, individuals with highest vs. lowest education had 96% vs. 92% primary coverage (adjRR 1.02, 95%CI 1.02-1.02) and 88% vs. 80% booster coverage (adjRR 1.09, 95%CI 1.09-1.09), while individuals with highest vs. lowest income had 98% vs. 82% primary coverage (adjRR 1.16, 95%CI 1.16-1.16) and 92% vs. 64% booster coverage (adjRR 1.33, 95%CI 1.33-1.34). In conclusion, we document large socioeconomic inequalities in COVID-19 vaccination coverage, especially for booster vaccination, even though all vaccination was free-of-charge. The results highlight the need to tailor information and to target underserved groups for booster vaccination. | ||
546 | |a EN | ||
690 | |a booster vaccine | ||
690 | |a vaccine hesitancy | ||
690 | |a social inequity | ||
690 | |a sociodemographic correlates | ||
690 | |a socioeconomic correlates | ||
690 | |a covid-19 | ||
690 | |a vaccination program | ||
690 | |a vaccine coverage | ||
690 | |a vaccine uptake | ||
690 | |a disparity | ||
690 | |a Immunologic diseases. Allergy | ||
690 | |a RC581-607 | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023) | |
787 | 0 | |n http://dx.doi.org/10.1080/21645515.2023.2188857 | |
787 | 0 | |n https://doaj.org/toc/2164-5515 | |
787 | 0 | |n https://doaj.org/toc/2164-554X | |
856 | 4 | 1 | |u https://doaj.org/article/b97c827da03e482b927ebe61bdbde1cf |z Connect to this object online. |